The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Abstract
Glutamatergic abnormalities have been associated with several psychiatric disorders, including schizophrenia and addiction. Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model. An agonist of this group of receptors, at a dose that was without effects on spontaneous activity and corticolimbic dopamine neurotransmission, attenuated the disruptive effects of phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux. This behavioral reversal occurred in spite of sustained dopamine hyperactivity. Thus, targeting this group of receptors may present a nondopaminergic therapeutic strategy for treatment of psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J.-P. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,081
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Self-citationGlutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Metabotropic glutamate receptors in brain function and pathology
Schoepp, D. D., & Conn, P. J. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90107-u · Cited by 791
Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., & Holzmüller, B. (1980) · Neuroscience Letters · doi:10.1016/0304-3940(80)90178-0 · Cited by 694
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
Petralia, R. S., Wang, Y.-X., Niedzielski, A. S., & Wenthold, R. J. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00533-1 · Cited by 579
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Molecular Diversity and Functions of Glutamate Receptors
Nakanishi, S., & Masu, M. (1994) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.bb.23.060194.001535 · Cited by 446
The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
Carlsson, M., & Carlsson, A. (1989) · Journal of Neural Transmission · doi:10.1007/bf01258633 · Cited by 423
Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia
Deakin, J. F. W., Slater, P., Simpson, M. D. C., Gilchrist, A. C., Skan, W. J., Royston, M. C., Reynolds, G. P., & Cross, A. J. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07257.x · Cited by 386
Schizophrenia and Glutamatergic Transmission
Tamminga, C. A. (1998) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v12.i1-2.20 · Cited by 385
The Case for Frontostriatal Dysfunction in Schizophrenia
Robbins, T. W. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.3.391 · Cited by 308
N‐Acetylaspartylglutamate Selectively Activates mGluR3 Receptors in Transfected Cells
Wroblewska, B., Wroblewski, J. T., Pshenichkin, S., Surin, A., Sullivan, S. E., & Neale, J. H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010174.x · Cited by 298
Helton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., & Kallman, M. J. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37253-2 · Cited by 279
Lovinger, D. M., & McCool, B. A. (1995) · Journal of Neurophysiology · doi:10.1152/jn.1995.73.3.1076 · Cited by 234
SCHOEPP, D. D., JOHNSON, B. G., WRIGHT, R. A., SALHOFF, C. R., MAYNE, N. G., WU, S., COCKERHAM, S. L., PAUL BURNETT, J., BELEGAJE, R., BLEAKMAN, D., et al. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00160-8 · Cited by 225
Battaglia, G., Monn, J. A., & Schoepp, D. D. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00442-4 · Cited by 163
Burns, R. S., & Lerner, S. E. (1976) · Clinical Toxicology · doi:10.3109/15563657608988151 · Cited by 129
Benes, F. M., Sorensen, I., Vincent, S. L., Bird, E. D., & Sathi, M. (1992) · Cerebral Cortex · doi:10.1093/cercor/2.6.503 · Cited by 128
Phencyclidine- and Dizocilpine-Induced Hyperlocomotion Are Differentially Mediated
Ögren, S. O., & Goldstein, M. (1994) · Neuropsychopharmacology · doi:10.1038/sj.npp.1380103 · Cited by 111
Willins, D. L., Narayanan, S., Wallace, L. J., & Uretsky, N. J. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90217-h · Cited by 89
East, S. J., Hill, M. P., & Brotchie, J. M. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00119-6 · Cited by 77
Yoshino, M., Sawada, S., Yamamoto, C., & Kamiya, H. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12486-1 · Cited by 70
Druhan, J. P., Rajabi, H., & Stewart, J. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199610)24:2<135::aid-syn5>3.0.co;2-g · Cited by 69
Iversen, S. D. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199508000-00009 · Cited by 54
Bubser, M., Tzschentke, T., & Hauber, W. (1995) · Journal of Neural Transmission · doi:10.1007/bf01271550 · Cited by 42
Lyon, N., Mejsholm, B., & Lyon, M. (1986) · Journal of Psychiatric Research · doi:10.1016/0022-3956(86)90013-0 · Cited by 41
Behavioural effects of NMDA-receptor antagonists.
Schmidt, W. J. (1994) · PubMed · Cited by 24
Hyperinnervation of orbital frontal cortex in schizophrenia
Deakin, J. F. W., Slater, P., Simpson, M. D. C., & Royston, M. C. (1990) · The British Journal of Psychiatry · doi:10.1192/bjp.157.3.459 · Cited by 6
Cited by
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Glutamate as a neurotransmitter in the brain: review of physiology and pathology
Meldrum, B. S. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.4.1007s · Cited by 1,667
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Self-citationMice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Metadata
- Authors
- Moghaddam, B., & Adams, B. W.
- Venue
- Science
- Published
- 1998-08-28
- Volume
- 281
- Issue
- 5381
- Pages
- 1349-1352
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061506085
- Cited by
- 1,006
- References
- 35
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.